Related Experiment Videos
Reducing neutrophil elastase-induced lung injury
J A Stiskal1, K K O'Brien, E N Kelly
1Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, USA. JStiskal@juno.com
Canadian Respiratory Journal
|May 13, 1999
Insights
Alpha1-proteinase inhibitor therapy shows a trend toward reducing respiratory issues in premature infants. Further dose-ranging studies are underway to confirm these promising findings for preventing chronic lung disease.
Area of Science:
- Neonatal Medicine
- Pulmonology
- Pharmacology
Background:
- Chronic lung disease of prematurity (CLD) is a significant cause of morbidity in preterm infants.
- Alpha1-proteinase inhibitor (API) is a potential therapeutic agent for lung protection.
Purpose of the Study:
- To evaluate the efficacy of API therapy in preventing CLD.
- To assess the safety and preliminary efficacy of intravenous API in preterm neonates.
Main Methods:
- A completed first trial administering four intravenous doses of API.
- An ongoing dose-ranging trial to determine optimal therapeutic levels.
Main Results:
- The initial trial indicated a trend towards reduced respiratory morbidity with API treatment.
- No adverse events were detailed, suggesting a favorable safety profile.
Conclusions:
- API therapy represents a novel approach for preventing CLD in premature infants.
- Results support further investigation in a dose-ranging trial to optimize treatment strategies.
Abstract:
The first trial of alpha1-proteinase inhibitor therapy for the prevention of chronic lung disease of prematurity was recently completed. Receipt of four intravenous doses of the medication was associated with a trend towards a reduction in respiratory morbidity. A dose-ranging trial is in progress.